

CANCER TYPE	At Least Two-Fold Upregulation	At Least Four-Fold Upregulation	Number Of Patients
COLON (TN)	47%	10%	19
COLON (MN) (liver)	74%	16%	19
PROSTATE (TN)	20%	0%	60
BREAST (TN)	20%	10%	10

Figure 1

Title: METHODS FOR TREATING
CANCER USING PORIMIN AS A
TARGET

Inventor(s): Eleni VENETSANAKOS

Appl. No.: Unassigned

Atty. Dkt. No.: 072121-0363

Levels of porimin mRNA in tumour cell lines normalized to actin





Figure 2


Figure 3

Anti-Porimin immunostaining in human cancer tissue

Breast Cancer



Thymic Cancer




Kidney Cancer



Lung Carcinoma



Undifferentiated Cancer



Ovarian Cancer






Figure 4
Anti-Porimin immunostaining in human cancer tissue

Breast cancer



Ovary cancer



Undif. carcinoma






Figure 5
Colocalization of Porimin with membrane CD44 in
paraffin section of PC3 xenograft



Confocal analysis – single stack at 63x

Figure 6
Colocalization of Porimin with membrane CD44 in
paraffin section of PC3 xenograft



Confocal analysis – single stack at 63x

Figure 7
 Anti-Porimin mAb induces cell death in Jurkat cells but
 not freshly isolated normal human PBL





Figure 8
Anti-Porimin mAb induces cell death in Jurkat cells but
not primary human renal epithelial cells



HRCE: primary human renal epithelial cells